GLP-1 Tracker

What GLP-1 Tracker does

GLP-1 Tracker is a privately held mobile application developed in 2025 by sole proprietor Hussain Mustafa for individuals managing therapy with GLP-1 receptor agonist medications, including Tirzepatide, Semaglutide, Ozempic, Wegovy, Mounjaro, and Zepbound. The product is a consumer health tracker focused on injection scheduling, dosage logging, side-effect journaling, weight-loss progress visualization, and treatment-history export for sharing with healthcare providers. It is available globally on Apple App Store and Google Play and is complemented by a web-based Medication Level Plotter that visualizes estimated pharmacokinetic drug levels over configurable 4-52 week windows using mathematical models and average pharmacokinetic data, with an educational-purpose disclaimer.

The underlying technology stack is conventional mobile-app architecture: native or cross-platform iOS and Android clients served through app stores, with Firebase Analytics, Firebase Crashlytics, and Google Play Services for telemetry and crash reporting, and RevenueCat for in-app subscription billing. The differentiating technical element is the pharmacokinetic visualization engine powering the Plotter, which is positioned as a novel educational tool rather than a medical device. No API, SDK, or healthcare-provider-facing integration is exposed, and the data model is local to the user's device with privacy-first, GDPR- and CCPA-aligned handling.

The business operates a pure product-led growth motion with no sales channel, marketing budget, or enterprise distribution. Monetization is freemium: core tracking functionality is free, with premium features sold as in-app purchases or subscriptions via RevenueCat. The company is bootstrapped, has not raised external capital, and reports 20,000+ users worldwide and a 4.8 star rating from 500+ reviews. There is one founder, no management team, no partnerships, and no M&A activity on record, making the business a single-individual sole proprietorship rather than a venture-scale entity.

Name

GLP-1 Tracker

Legal name

Hussain Mustafa

Website

https://glp1plotter.app

Company type

Private

Founded year

2025

Operating status

Operating

Short description

GLP-1 Tracker is a freemium iOS and Android mobile app, developed by sole proprietor Hussain Mustafa, that helps individual patients track GLP-1 medication injections, dosages, weight-loss progress, and treatment history for sharing with healthcare providers.

Ownership category

akta.pro rank

Product category

Medication Management Software

NAICS

Software Publishers (5132)

akta.pro primary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Medication tracking app
• GLP-1 therapy management
• Injection tracking software
• Weight loss monitoring
• Pharmacokinetic visualization

GTM type

B2C

Offering type

Software

Cost components

Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Freemium App Model: Application offered as a Freemium service with core tracking features available at no cost and premium features available for purchase. Users can download and use basic functionality for free; monetization occurs through in-app purchases or subscriptions for advanced features.

Go-to-market motion1 record

Distribution channels2 records

Core offering

GLP-1 Tracker is a freemium mobile application for iOS and Android that enables individual users to track their GLP-1 medication journey, including injection schedules, dosages, side effects, and weight loss progress. The app also features a companion web-based Medication Level Plotter that uses mathematical pharmacokinetic models to visualize estimated medication levels in the user's system over configurable 4-52 week time ranges. The product is built around privacy-first data storage with industry-standard encryption and supports multiple major GLP-1 brands including Tirzepatide, Semaglutide, Ozempic, Wegovy, Mounjaro, and Zepbound.

Product overview

GLP-1 Tracker offers a unified mobile application platform for tracking GLP-1 medications (Tirzepatide, Semaglutide, Ozempic, Wegovy, Mounjaro, Zepbound) paired with a companion web-based medication level plotting tool. The mobile app provides comprehensive injection tracking, weight progress monitoring, smart reminders, detailed analytics, and treatment history features. The Medication Level Plotter is a complementary educational tool that visualizes estimated pharmacokinetic levels. The product operates on a Freemium model, available on iOS (App Store) and Android (Google Play) platforms.

Differentiator

Problem solved

Functional benefit

Products and services

• GLP-1 Tracker Mobile Application A comprehensive freemium mobile app for iOS and Android that enables individual users to track GLP-1 medications (Tirzepatide, Semaglutide, Ozempic, Wegovy, Mounjaro, Zepbound) including injection schedules, dosages, side effects, and weight loss progress. Features include smart reminders, detailed analytics, treatment history, and exportable reports for healthcare provider sharing.
• GLP-1 Medication Level Plotter A web-based educational tool that visualizes estimated medication levels in the user's system over time based on defined injection schedules. Uses mathematical models and average pharmacokinetic data to show how different GLP-1 medications affect blood concentration over configurable time ranges (4-52 weeks). For educational purposes only.

Quantifiable outcome

• Trusted by 20,000+ users worldwide
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Feature7 records

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Pepound: Pepound is a GLP-1 shot tracking app with similar injection, dosage, and weight-loss tracking features. It is a near-identical substitute for GLP-1 Tracker and the most direct head-to-head rival on the App Store.
• MyTherapy: MyTherapy combines medication reminders, symptom tracking, and treatment journals in a mobile app format. Overlaps with GLP-1 Tracker on injection scheduling, side-effect logging, and treatment history.
• Shotsy: Shotsy is a direct competitor offering GLP-1 injection and weight tracking across the same major brands (Ozempic, Wegovy, Mounjaro, Zepbound). It targets the identical consumer use case and competes head-to-head for the same organic search demand.
• Medisafe: Medisafe is a medication adherence and tracking platform used by millions of patients. While not GLP-1 specific, it is the dominant horizontal medication reminder/tracker and competes for the same patient mindshare.
• Happy Scale: Happy Scale is a weight-tracking iOS app focused on trend smoothing and long-term progress visualization. It overlaps with GLP-1 Tracker's weight progress feature and is often an alternative install for the same user intent.

Broad incumbents

• Noom: Noom is a weight-loss app that has explicitly added GLP-1 support programs. It is a broader incumbent that overlaps with GLP-1 Tracker on weight progress monitoring and patient engagement, with a much larger paid user base.
• MyFitnessPal: MyFitnessPal is the largest consumer weight and nutrition tracking platform. It is not GLP-1 specific but competes for the same weight-management user intent and could trivially add injection tracking.
• Lose It!: Lose It! is a mainstream calorie and weight tracking app with tens of millions of users. It is a horizontal incumbent whose weight-loss focus puts it in competition for the same GLP-1 patient audience.
• WW (WeightWatchers): WW is an established weight-management brand that has launched GLP-1-friendly program tiers. It competes for the same end user and brings a much larger brand and clinical-coaching infrastructure.
• Apple Health: Apple Health is the default health data platform on iOS and the underlying substrate that surfaces medication and weight data. It does not target GLP-1 specifically today but represents the largest platform-level competitive threat.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GLP-1 Tracker